Zhengye Biotechnology Holding Limited Ordinary Shares - Asset Resilience Ratio
Zhengye Biotechnology Holding Limited Ordinary Shares (ZYBT) has an Asset Resilience Ratio of 0.29% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See financial flexibility index of Zhengye Biotechnology Holding Limited Or to measure the company's free cash flow as a share of total liabilities.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2025)
This chart shows how Zhengye Biotechnology Holding Limited Ordinary Shares's Asset Resilience Ratio has changed over time. See ZYBT equity to assets ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Zhengye Biotechnology Holding Limited Ordinary Shares's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ZYBT company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.43 Million | 0.29% |
| Total Liquid Assets | $1.43 Million | 0.29% |
Asset Resilience Insights
- Limited Liquidity: Zhengye Biotechnology Holding Limited Ordinary Shares maintains only 0.29% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Zhengye Biotechnology Holding Limited Ordinary Shares Industry Peers by Asset Resilience Ratio
Compare Zhengye Biotechnology Holding Limited Ordinary Shares's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Huadong Medicine Co Ltd
SHE:000963 |
Drug Manufacturers - Specialty & Generic | 0.05% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436 |
Drug Manufacturers - Specialty & Generic | -2.56% |
|
Celltrion Pharm Inc
KQ:068760 |
Drug Manufacturers - Specialty & Generic | 12.49% |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799 |
Drug Manufacturers - Specialty & Generic | 0.40% |
Annual Asset Resilience Ratio for Zhengye Biotechnology Holding Limited Ordinary Shares (2022–2025)
The table below shows the annual Asset Resilience Ratio data for Zhengye Biotechnology Holding Limited Ordinary Shares.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.29% | $1.43 Million | $493.25 Million | 0.00pp |
| 2024-12-31 | 0.29% | $1.43 Million | $493.25 Million | +0.05pp |
| 2023-12-31 | 0.24% | $1.22 Million | $499.89 Million | -- |
| 2022-12-31 | 0.00% | $0.00 | $519.67 Million | -- |
About Zhengye Biotechnology Holding Limited Ordinary Shares
Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs. Its veterinary vaccines include monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine. The company also develops vaccines for househol… Read more